Background
Background The relative efficacy of
The relative efficacy of psychotherapy and combined therapy in psychotherapy and combined therapy in the treatment of depression is still a matter the treatment of depression is still a matter of debate. of debate.
Aims Aims To investigate whether combined
To investigate whether combined therapy has advantages over therapy has advantages over psychotherapy alone. psychotherapy alone.
Method
Method A 6 -month randomised A 6 -month randomised clinical trial compared Short clinical trial compared Short Psychodynamic Supportive Psychodynamic Supportive Psychotherapy ( Psychotherapy (n n¼106) with combined 106) with combined therapy ( therapy (n n¼85) in ambulatory patients 85) in ambulatory patients with mild or moderate major depressive with mild or moderate major depressive disorder diagnosed using DSM^IV disorder diagnosed using DSM^IV criteria. Antidepressants were prescribed criteria. Antidepressants were prescribed according to a protocol providing four according to a protocol providing four successive steps in case of intolerance or successive steps in case of intolerance or inefficacy: venlafaxine, selective serotonin inefficacy: venlafaxine, selective serotonin reuptake inhibitor, nortriptyline and reuptake inhibitor, nortriptyline and nortriptyline plus lithium. Efficacy was nortriptyline plus lithium. Efficacy was assessed using the17-item Hamilton assessed using the17-item Hamilton Rating Scale for Depression, the Clinical Rating Scale for Depression, the Clinical Global Impression of Severity and of Global Impression of Severity and of Improvement, and the depression subImprovement, and the depression subscale of the Symptom Checklist. scale of the Symptom Checklist.
Results

Results The advantages of combining
The advantages of combining antidepressants with psychotherapy were antidepressants with psychotherapy were equivocal.Neither the treating clinicians equivocal.Neither the treating clinicians nor the independent observers were able nor the independent observers were able to ascertain them, butthe patients to ascertain them, butthe patients experienced them clearly. experienced them clearly.
Conclusions Conclusions The advantages of
The advantages of combining antidepressants with combining antidepressants with psychotherapy are equivocal. psychotherapy are equivocal.
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According to clinical lore, the combination According to clinical lore, the combination of antidepressants and psychotherapy is of antidepressants and psychotherapy is preferable to psychotherapy alone in the preferable to psychotherapy alone in the treatment of depression. However, this treatment of depression. However, this view is not corroborated by empirical eviview is not corroborated by empirical evidence. We found seven studies addressing dence. We found seven studies addressing this issue. Keller this issue. Keller et al et al (2000) , Blackburn (2000) , Blackburn et et al al (1981) and Weissman (1981) and Weissman et al et al (1979) (1979) reported a superior efficacy of combined reported a superior efficacy of combined therapy. On the other hand, Thase therapy. On the other hand, Thase et al et al (1997) , Hollon (1997) , Hollon et al et al (1993) , Beck (1993) , Beck et al et al (1985) and Murphy (1985) and Murphy et al et al (1981 Murphy et al et al ( ) reported (1981 reported equal efficacy of the treatments. Thase equal efficacy of the treatments. Thase et et al al (1997) , who found no difference in their (1997) , who found no difference in their total group, specified that combined total group, specified that combined therapy was more efficacious than psychotherapy was more efficacious than psychotherapy only when the depression was therapy only when the depression was severe. This paper reports the results of a severe. This paper reports the results of a trial comparing the 6-month efficacy of trial comparing the 6-month efficacy of psychotherapy with that of combined psychotherapy with that of combined therapy in patients with major depressive therapy in patients with major depressive disorder of mild or moderate severity, disorder of mild or moderate severity, defined according to DSM-IV criteria defined according to DSM-IV criteria (American Psychiatric Association, 1994) . (American Psychiatric Association, 1994) . The study is part of the long-term DepresThe study is part of the long-term Depression Research Project of the Mentrum sion Research Project of the Mentrum Mental Health Organisation, which studies Mental Health Organisation, which studies the relative value of pharmacotherapy, the relative value of pharmacotherapy, psychotherapy and combined therapy in psychotherapy and combined therapy in depression (de Jonghe depression (de Jonghe et al et al, 2001; Kool , 2001; Kool et al et al, 2003 Kool et al et al, ). , 2003 .
METHOD METHOD Sample Sample
The study sample consisted of all consecuThe study sample consisted of all consecutive patients newly registered during a 3-tive patients newly registered during a 3-year period at two out-patient clinics of year period at two out-patient clinics of the Mentrum Mental Health Organisation the Mentrum Mental Health Organisation in Amsterdam. Mentrum is a large psychiin Amsterdam. Mentrum is a large psychiatric facility with several in-patient and atric facility with several in-patient and out-patient clinics, covering a third of the out-patient clinics, covering a third of the population of Amsterdam, mainly the inner population of Amsterdam, mainly the inner city. The inclusion criteria were age 18-65 city. The inclusion criteria were age 18-65 years, DSM-IV major depressive disorder years, DSM-IV major depressive disorder with or without dysthymia, a baseline score with or without dysthymia, a baseline score on the 17-item Hamilton Rating Scale for on the 17-item Hamilton Rating Scale for Depression (HRSD; Hamilton, 1967) of Depression (HRSD; Hamilton, 1967) of 12-24 points, and written informed con-12-24 points, and written informed consent. Patients were excluded if they had a sent. Patients were excluded if they had a psycho-organic disorder, drug misuse, a psycho-organic disorder, drug misuse, a psychotic disorder or a dissociative dispsychotic disorder or a dissociative disorder; if they were considered too unorder; if they were considered too unreliable to participate in a clinical trial reliable to participate in a clinical trial (e.g. 'doctor shopping'); if they could not (e.g. 'doctor shopping'); if they could not participate in the trial owing to a serious participate in the trial owing to a serious communicative problem (e.g. language communicative problem (e.g. language barrier) or physical restrictions (e.g. the barrier) or physical restrictions (e.g. the patient will soon leave the country); if any patient will soon leave the country); if any of the antidepressants prescribed by the of the antidepressants prescribed by the pharmacotherapy protocol was contrapharmacotherapy protocol was contraindicated; if the patient was treated adeindicated; if the patient was treated adequately with antidepressants during the quately with antidepressants during the present depressive episode; if they used present depressive episode; if they used psychotropic medication other than drugs psychotropic medication other than drugs prescribed by the pharmacotherapy protoprescribed by the pharmacotherapy protocol; and if they were wishing to become col; and if they were wishing to become pregnant. Patients were also excluded if pregnant. Patients were also excluded if they were considered by the psychiatrist to they were considered by the psychiatrist to be 'too ill' or 'too suicidal' (e.g. hospitalisabe 'too ill' or 'too suicidal' (e.g. hospitalisation is unavoidable) to participate in a tion is unavoidable) to participate in a clinical trial. clinical trial. The flow of the patients through the The flow of the patients through the first stages of the trial is shown in Fig. 1 . first stages of the trial is shown in Fig. 1 .
The application of these criteria, other The application of these criteria, other than the HRSD baseline scores, to 4035 than the HRSD baseline scores, to 4035 newly registered out-patients selected 372 newly registered out-patients selected 372 patients. Of these, 69 patients (18%) were patients. Of these, 69 patients (18%) were excluded because of an HRSD baseline excluded because of an HRSD baseline score lower than 12 points, and 70 (19%) score lower than 12 points, and 70 (19%) because of a score higher than 24 points, because of a score higher than 24 points, leaving 233 patients who were asked to leaving 233 patients who were asked to consent to randomisation. This means that, consent to randomisation. This means that, apart from other criteria, nearly a quarter apart from other criteria, nearly a quarter of the patients presenting with a major of the patients presenting with a major depressive episode and an HRSD baseline depressive episode and an HRSD baseline score of at least 12 points were excluded score of at least 12 points were excluded because of the severity of their illness. The because of the severity of their illness. The inclusion and exclusion criteria are the inclusion and exclusion criteria are the usual ones in clinical pharmacotherapy usual ones in clinical pharmacotherapy research. In regard to psychotherapy, no research. In regard to psychotherapy, no selection criterion was applied. Factors selection criterion was applied. Factors such as ego strength, introspection, such as ego strength, introspection, psychological-mindedness or verbal abilpsychological-mindedness or verbal abilities were not taken into account. After a ities were not taken into account. After a complete description of the study to the complete description of the study to the patients, written informed consent was patients, written informed consent was obtained. After randomisation, 17 patients obtained. After randomisation, 17 patients refused the allocated intervention (see refused the allocated intervention (see results). results).
Study design Study design
This 6-month trial had a randomised, This 6-month trial had a randomised, parallel group design. It was preceded by parallel group design. It was preceded by a 2-week period in which the diagnosis a 2-week period in which the diagnosis was assessed by means of a semi-structured was assessed by means of a semi-structured interview (Huyser interview (Huyser et al et al, 1996) , the , 1996), the inclusion and exclusion criteria were inclusion and exclusion criteria were checked, and the baseline assessments were checked, and the baseline assessments were made. This period was used, if necessary, as made. This period was used, if necessary, as a drug wash-out period (without placebo). a drug wash-out period (without placebo). A 6-month follow-up after the end of the A 6-month follow-up after the end of the trial is intended. trial is intended.
All patients were treated by experienced All patients were treated by experienced psychodynamic psychotherapists or by resipsychodynamic psychotherapists or by residents who were supervised once a week. dents who were supervised once a week. The psychotherapy provided was Short The psychotherapy provided was Short Psychodynamic Supportive Psychotherapy Psychodynamic Supportive Psychotherapy (SPSP), a draft of which is available -in (SPSP), a draft of which is available -in Dutch -from the authors upon written Dutch -from the authors upon written request. It is based on the principles enunrequest. It is based on the principles enunciated by, among others, Werman (1984) , ciated by, among others, Werman (1984) , Strupp & Binder (1984) , Rockland (1989 ) Strupp & Binder (1984 , Rockland (1989) and de Jonghe and de Jonghe et al et al (1994) . It consists of (1994) . It consists of up to 16 sessions delivered within a 6-up to 16 sessions delivered within a 6-month period. Termination of the therapy month period. Termination of the therapy in fewer sessions, if there is agreement in fewer sessions, if there is agreement between patient and therapist, is allowed. between patient and therapist, is allowed. All psychotherapy sessions in the trial were All psychotherapy sessions in the trial were audiotaped. The therapists met weekly for audiotaped. The therapists met weekly for an hour-long discussion of their tapes; an hour-long discussion of their tapes; F.deJ., a fully trained psychoanalyst who F.deJ., a fully trained psychoanalyst who formulated the guidelines for SPSP, particiformulated the guidelines for SPSP, participated in most of these meetings, listening to pated in most of these meetings, listening to several tapes for each of the psychoseveral tapes for each of the psychotherapists, and was especially attentive to therapists, and was especially attentive to the adherence to the manual. the adherence to the manual.
In the combined therapy condition the In the combined therapy condition the psychotherapy started within 2 weeks of psychotherapy started within 2 weeks of the start of pharmacotherapy. All patients the start of pharmacotherapy. All patients receiving combined therapy were given, in receiving combined therapy were given, in addition to SPSP, antidepressant mediaddition to SPSP, antidepressant medication prescribed according to the protocol cation prescribed according to the protocol set out in the Appendix. The intended set out in the Appendix. The intended medication period was 6 months. The promedication period was 6 months. The protocol provides for four consecutive steps to tocol provides for four consecutive steps to allow for intolerance or inefficacy. The first allow for intolerance or inefficacy. The first step is the prescription of the serotoninstep is the prescription of the serotoninnoradrenaline reuptake inhibitor venlanoradrenaline reuptake inhibitor venlafaxine. Depending on the patient's faxine. Depending on the patient's response, this therapy continues at the same response, this therapy continues at the same or an increased dosage, or the patient is or an increased dosage, or the patient is switched to step 2, in which a selective switched to step 2, in which a selective serotonin reuptake inhibitor (SSRI) is subserotonin reuptake inhibitor (SSRI) is substituted (for details, see Appendix). In the stituted (for details, see Appendix). In the event of SSRI intolerance or inefficacy, the event of SSRI intolerance or inefficacy, the medication is changed to the tricyclic medication is changed to the tricyclic antidepressant nortriptyline in step 3, and antidepressant nortriptyline in step 3, and if this too is inefficacious, lithium is added if this too is inefficacious, lithium is added to step 4. The sequence in this protocol is to step 4. The sequence in this protocol is arbitrary, but not unfounded. Venlafaxine arbitrary, but not unfounded. Venlafaxine is an efficacious and safe antidepressant is an efficacious and safe antidepressant with a relatively mild side-effect profile. In with a relatively mild side-effect profile. In lower dosage it acts as an SSRI, at higher lower dosage it acts as an SSRI, at higher dosage it also acts as a noradrenaline redosage it also acts as a noradrenaline reuptake inhibitor (Harvey uptake inhibitor (Harvey et al et al, 2000) . , 2000). Nortriptyline is less safe and presents Nortriptyline is less safe and presents burdensome side-effects, but its efficacy is burdensome side-effects, but its efficacy is undisputed. Lithium addition is the bestundisputed. Lithium addition is the beststudied addition procedure (for augmenting studied addition procedure (for augmenting tricyclic antidepressant therapy). The psytricyclic antidepressant therapy). The psychiatrist makes eight follow-up appointchiatrist makes eight follow-up appointments of 15 min each with the patient, the ments of 15 min each with the patient, the first four at 2-week intervals, the last four first four at 2-week intervals, the last four at monthly intervals. If considered necesat monthly intervals. If considered necessary by the psychiatrist, e.g. when medisary by the psychiatrist, e.g. when medication change is required, additional cation change is required, additional appointments are permitted. The task of appointments are permitted. The task of the psychiatrist is to provide pharmacothe psychiatrist is to provide pharmacotherapy and clinical management. The therapy and clinical management. The latter consists of psycho-education, discusslatter consists of psycho-education, discussing the effects and side-effects of medicaing the effects and side-effects of medication, motivating the patient to comply tion, motivating the patient to comply with the medication regimen, and providing with the medication regimen, and providing practical and emotional support. practical and emotional support.
Outcome measures Outcome measures
Efficacy was defined by intra-and interEfficacy was defined by intra-and intergroup differences at several assessment group differences at several assessment points. The principal outcome measure points. The principal outcome measure was the difference between the assessments was the difference between the assessments at baseline and those at week 24. The priat baseline and those at week 24. The primary instrument was the 17-item Hamilton mary instrument was the 17-item Hamilton Rating Scale for Depression (HRSD; Rating Scale for Depression (HRSD; Hamilton, 1967) , rated by three indepenHamilton, 1967), rated by three independent observers, using a semi-structured dent observers, using a semi-structured interview (de Jonghe, 1994; Kupka interview (de Jonghe, 1994; Kupka et al et al, , 1996) . The reliability of these raters ' assess-1996) . The reliability of these raters' assessments was established before the study ments was established before the study began and during the study they discussed began and during the study they discussed their audiotaped assessments monthly with their audiotaped assessments monthly with one of the authors (F.deJ.). Although the one of the authors (F.deJ.). Although the patients and the treating physicians were patients and the treating physicians were not masked to randomisation, the raters not masked to randomisation, the raters were not informed about the treatment conwere not informed about the treatment condition and were instructed to restrict themdition and were instructed to restrict themselves to discussion of the HRSD items selves to discussion of the HRSD items only. The magnitude of the differences is only. The magnitude of the differences is expressed in effect sizes. Efficacy is also exexpressed in effect sizes. Efficacy is also expressed in success rates. Success (remission) pressed in success rates. Success (remission) is defined as an HRSD final score of 7 is defined as an HRSD final score of 7 points or less. points or less.
The second instrument used was the The second instrument used was the Clinical Global Impression (CGI; Guy, Clinical Global Impression (CGI; Guy, 1976) , both of severity (CGI-S) and of 1976), both of severity (CGI-S) and of 3 8 3 8 1986) . Success according to these instru-1986). Success according to these instruments was defined as a final score of 1-2 ments was defined as a final score of 1-2 on the CGI-S or CGI-I, and as an improveon the CGI-S or CGI-I, and as an improvement of at least 1 standard deviation on the ment of at least 1 standard deviation on the SCL-D. In short, efficacy assessments were SCL-D. In short, efficacy assessments were based on data drawn from three sources: based on data drawn from three sources: the treating clinicians, the patients and the treating clinicians, the patients and independent observers. The assessments independent observers. The assessments were made at weeks 4, 8, 12 and 24. were made at weeks 4, 8, 12 and 24. At each assessment 17 somatic comAt each assessment 17 somatic complaints, whether or not related to therapy, plaints, whether or not related to therapy, were systematically inquired about and were systematically inquired about and rated on a five-point scale (1, absent; 5, rated on a five-point scale (1, absent; 5, extreme). These complaints were nausea, extreme). These complaints were nausea, headache, diarrhoea, constipation, dizziheadache, diarrhoea, constipation, dizziness, dry mouth, skin anomalies, eye ness, dry mouth, skin anomalies, eye problems, excessive sweating, drowsiness, problems, excessive sweating, drowsiness, shaking or trembling, loss of libido, fever, shaking or trembling, loss of libido, fever, weight gain, weight loss, loss of appetite weight gain, weight loss, loss of appetite and 'other complaints'. Scores 1 and 2 were and 'other complaints'. Scores 1 and 2 were subsequently converted to 0 (absent) and subsequently converted to 0 (absent) and scores 3, 4 and 5 to 1 (present), before scores 3, 4 and 5 to 1 (present), before calculating a mean score for each treatment calculating a mean score for each treatment group. group.
improvement (CGI-I
Statistical analysis Statistical analysis
Analysis of covariance (ANCOVA), inAnalysis of covariance (ANCOVA), including the initial measures as covariants, cluding the initial measures as covariants, and multivariate analyses of variance and multivariate analyses of variance (MANOVA) were used to test intra-group (MANOVA) were used to test intra-group and inter-group differences. In addition, and inter-group differences. In addition, one-group pre-post effect sizes and comone-group pre-post effect sizes and comparative effect sizes (Cohen's parative effect sizes (Cohen's d d; Cohen, ; Cohen, 1988) were calculated as the standard dif-1988) were calculated as the standard difference between two means, using the ference between two means, using the pooled standard deviation as denominator pooled standard deviation as denominator (Rosnow & Rosenthal, 1996) . Pearson (Rosnow & Rosenthal, 1996) . Pearson chi-squared calculations (two-sided, level chi-squared calculations (two-sided, level of significance of significance P P5 50.05) were used to com-0.05) were used to compare refusal rates, base rates, withdrawal pare refusal rates, base rates, withdrawal rates, success rates and somatic complaints; rates, success rates and somatic complaints; analysis of variance was used to compare analysis of variance was used to compare mean age, total number of somatic commean age, total number of somatic complaints and psychotherapy sessions. Finally, plaints and psychotherapy sessions. Finally, using the HRSD remission rates and the using the HRSD remission rates and the SCL-D success rates, Kaplan-Meier survi-SCL-D success rates, Kaplan-Meier survival estimates were calculated, and the val estimates were calculated, and the curves obtained were compared using the curves obtained were compared using the log-rank test to take into account both log-rank test to take into account both the rate of remission and the time needed the rate of remission and the time needed to achieve remission. to achieve remission.
Our main results were calculated in a Our main results were calculated in a per protocol sample, which consists of all per protocol sample, which consists of all patients who started with the treatment patients who started with the treatment they were allotted to. Secondary results they were allotted to. Secondary results were calculated in an intention-to-treat were calculated in an intention-to-treat sample, which consisted of all randomised sample, which consisted of all randomised patients. In both of these samples the 'last patients. In both of these samples the 'last observation carried forward' method was observation carried forward' method was applied. Secondary results were also calcuapplied. Secondary results were also calculated in an observed-cases sample, which lated in an observed-cases sample, which consisted of all patients who completed consisted of all patients who completed the treatment, and in this sample only the the treatment, and in this sample only the observed data were used. observed data were used.
Patients were considered to have withPatients were considered to have withdrawn from pharmacotherapy if they drawn from pharmacotherapy if they stopped taking medication for any reason, stopped taking medication for any reason, or experienced no benefit after the four or experienced no benefit after the four treatment steps in the protocol. Patients treatment steps in the protocol. Patients were considered to have withdrawn from were considered to have withdrawn from psychotherapy if they stopped attending psychotherapy if they stopped attending the sessions without the agreement of their the sessions without the agreement of their therapist, but not if therapy was terminated therapist, but not if therapy was terminated before session 16 or before week 24 by before session 16 or before week 24 by mutual agreement. Patients randomised to mutual agreement. Patients randomised to the combined therapy condition could the combined therapy condition could withdraw from both aspects of treatment. withdraw from both aspects of treatment.
At the start of the study, we expected a At the start of the study, we expected a recovery rate difference of about 15%, with recovery rate difference of about 15%, with a success rate about 65% in the combined a success rate about 65% in the combined condition and 50% in the psychotherapy condition and 50% in the psychotherapy condition. Based on 0.75 power to detect condition. Based on 0.75 power to detect a significant difference ( a significant difference (P P¼0.05, one-0.05, onesided), the intention was to involve about sided), the intention was to involve about 200 participants in the study (100 in each 200 participants in the study (100 in each condition). condition).
RESULTS RESULTS
A total of 208 participants were assigned to A total of 208 participants were assigned to psychotherapy ( psychotherapy (n n¼107) or combined 107) or combined therapy ( therapy (n n¼101) using block randomis-101) using block randomisation. Four blocks were formed, defined ation. Four blocks were formed, defined by gender and age. Of the randomised by gender and age. Of the randomised patients, 17 refused the proposed treatpatients, 17 refused the proposed treatment: one in the psychotherapy group and ment: one in the psychotherapy group and 16 in the combined therapy group 16 in the combined therapy group
15.30, d.f.¼1; 1; P P5 50.001). Almost 0.001). Almost all of those refusing the combined therapy all of those refusing the combined therapy objected to taking medication rather objected to taking medication rather than the psychotherapeutic aspect. There than the psychotherapeutic aspect. There was no significant difference between was no significant difference between those who refused and those who those who refused and those who accepted the proposed treatment, whether accepted the proposed treatment, whether in clinical variables, psychiatric history or in clinical variables, psychiatric history or demographic characteristics. demographic characteristics.
The characteristics of the 191 patients The characteristics of the 191 patients in the per protocol sample are given in in the per protocol sample are given in Table 2 . Three-quarters rates are shown in Table 2 . Three-quarters of the patients in the psychotherapy condiof the patients in the psychotherapy condition and 84% in the combined therapy contion and 84% in the combined therapy condition terminated their psychotherapy with dition terminated their psychotherapy with the agreement of their therapist; this differthe agreement of their therapist; this difference is not statistically significant. These ence is not statistically significant. These patients had a mean of 13 psychotherapy patients had a mean of 13 psychotherapy sessions in both treatment conditions. sessions in both treatment conditions. Pharmacotherapy withdrawal rates are Pharmacotherapy withdrawal rates are shown in Table 3 . The rate was less than shown in Table 3 . The rate was less than 10% after 8 weeks, but climbed to 35% 10% after 8 weeks, but climbed to 35% at week 24. at week 24. Table 4 presents the efficacy results, Table 4 presents the efficacy results, expressed in mean HRSD, CGI and SCL expressed in mean HRSD, CGI and SCL scores. Intra-group differences between scores. Intra-group differences between baseline and week-24 assessments are stabaseline and week-24 assessments are statistically significant in both treatment contistically significant in both treatment conditions for both the per protocol and ditions for both the per protocol and observed-cases samples. Inter-group differobserved-cases samples. Inter-group differences at week 24 are statistically significant ences at week 24 are statistically significant (ANCOVA) in the per protocol sample (ANCOVA) in the per protocol sample according to the CGI-I ( according to the CGI-I (P P5 50.05) and the 0.05) and the SCL-D ( SCL-D (P P5 50.001). In the observed-cases 0.001). In the observed-cases sample, statistically significant inter-group sample, statistically significant inter-group differences at week 24 are shown by the differences at week 24 are shown by the HRSD ( HRSD (P P5 50.046) and the SCL-D 0.046) and the SCL-D ( (P P5 50.001). In the intention-to-treat sample 0.001). In the intention-to-treat sample no difference between the two treatment no difference between the two treatment groups was found at any point by any groups was found at any point by any assessment method (according to the assessment method (according to the Bonferroni-adjusted Bonferroni-adjusted P P value). value). As we calculated As we calculated P P separately for each separately for each time point and outcome in this table, a time point and outcome in this table, a Bonferroni correction seems prudent. With Bonferroni correction seems prudent. With 15 assessments in each sample and a mean 15 assessments in each sample and a mean intercorrelation of about 0.4 between the intercorrelation of about 0.4 between the assessments, a probability of about 0.01 is assessments, a probability of about 0.01 is more accurate, in which case only the more accurate, in which case only the difference in SCL-D scores in this table is difference in SCL-D scores in this table is relevant. This is also the case with the relevant. This is also the case with the MANOVA analyses: only the SCL-D score MANOVA analyses: only the SCL-D score shows significant inter-group differences shows significant inter-group differences ( (F F¼4.32, d.f.
4.32, d.f.¼1; 1; P P¼0.008). Table 5 pre-0.008). Table 5 presents the efficacy results in the per protocol sents the efficacy results in the per protocol sample, expressed in effect sizes. sample, expressed in effect sizes. Table 6 presents the efficacy results, Table 6 presents the efficacy results, expressed in success rates. In the per protoexpressed in success rates. In the per protocol sample, the success rates at week 24 col sample, the success rates at week 24 vary between 32% and 69% in the psyvary between 32% and 69% in the psychotherapy condition, and between 42% chotherapy condition, and between 42% and 79% in the combined therapy condiand 79% in the combined therapy condition. If CGI success is defined as a score tion. If CGI success is defined as a score of 1 or 2 on either the severity or the imof 1 or 2 on either the severity or the improvement scale, the success rates at week provement scale, the success rates at week 24 rise to 73% for psychotherapy and to 24 rise to 73% for psychotherapy and to 81% for combined therapy. Statistically 81% for combined therapy. Statistically significant excess success rates at week 24 significant excess success rates at week 24
are shown by the SCL-D in both samples are shown by the SCL-D in both samples (with (with P P values close to the Bonferronivalues close to the Bonferroniadjusted value of 0.01), and in neither adjusted value of 0.01), and in neither sample by the other scales. sample by the other scales.
An overview of the main results is preAn overview of the main results is presented in Table 7 . In the intention-to-treat sented in Table 7 . In the intention-to-treat sample no difference between the two treatsample no difference between the two treatment groups was found at any moment by ment groups was found at any moment by any assessment method (according to the any assessment method (according to the Bonferroni-adjusted Bonferroni-adjusted P P value). The Kaplanvalue). The KaplanMeier survival curves for the two treatment Meier survival curves for the two treatment groups (of the per protocol sample) in terms groups (of the per protocol sample) in terms of HRSD remission and SCL-D success are of HRSD remission and SCL-D success are shown in Figs 2 and 3. shown in Figs 2 and 3 .
In analysis of the Kaplan-Meier surviIn analysis of the Kaplan-Meier survival estimates based on the HRSD, the mean val estimates based on the HRSD, the mean time needed to achieve remission was 138 time needed to achieve remission was 138 days in the psychotherapy group and 129 days in the psychotherapy group and 129 days in the combined therapy group. There days in the combined therapy group. There is no significant difference between the two is no significant difference between the two treatment groups in the distribution of time treatment groups in the distribution of time to remission (log rank to remission (log rank¼2.39, d.f.
2.39, d.f.¼1, 1, P P¼0.122). In the estimates based on the 0.122). In the estimates based on the SCL-D the mean time needed to achieve SCL-D the mean time needed to achieve success was 120 days in the psychotherapy success was 120 days in the psychotherapy group and 104 days in the combined thergroup and 104 days in the combined therapy group. From week 4 on, the differences apy group. From week 4 on, the differences between the two treatment groups are between the two treatment groups are significant (log rank significant (log rank¼5.30, d.f.
5.30, d.f.¼1, 1, P P¼ 0.021). In both treatment groups, somatic 0.021). In both treatment groups, somatic complaints decreased between the baseline complaints decreased between the baseline and end-point assessments. No statistically and end-point assessments. No statistically significant inter-group difference between significant inter-group difference between the mean scores of somatic complaints the mean scores of somatic complaints was found at any assessment point. As far was found at any assessment point. As far as individual items are concerned, 6 of the as individual items are concerned, 6 of the 17 complaints were significantly more 17 complaints were significantly more frequent in one of the two treatment frequent in one of the two treatment conditions: dry mouth and excessive conditions: dry mouth and excessive sweating in combined therapy, and headsweating in combined therapy, and headache, nausea, trembling or shaking and ache, nausea, trembling or shaking and 'other complaints' in psychotherapy. 'other complaints' in psychotherapy.
Follow-up data on this study sample are Follow-up data on this study sample are still being gathered. still being gathered.
DISCUSSION DISCUSSION
Sample selection Sample selection
The inclusion and exclusion criteria applied The inclusion and exclusion criteria applied in this study led to selection bias: our study in this study led to selection bias: our study population was restricted to ambulatory population was restricted to ambulatory patients presenting with a major depressive patients presenting with a major depressive disorder of mild or moderate severity and, disorder of mild or moderate severity and, in 75% of cases, a duration of less than 2 in 75% of cases, a duration of less than 2 years. Nearly a quarter (23%) of potenyears. Nearly a quarter (23%) of potentially eligible patients were excluded on tially eligible patients were excluded on account of an HRSD baseline score of 25 account of an HRSD baseline score of 25 points or more. This means that our results points or more. This means that our results may be cautiously generalised, as far as may be cautiously generalised, as far as 4 0 4 0 severity is concerned, to 77% of the severity is concerned, to 77% of the patients registered at our out-patient clinics patients registered at our out-patient clinics with a major depressive disorder and an with a major depressive disorder and an HRSD baseline score of 12 points or more. HRSD baseline score of 12 points or more.
Study design Study design
Our study addresses the pragmatic question Our study addresses the pragmatic question of the differential clinical utility of two fully of the differential clinical utility of two fully realised treatment packages, both represenrealised treatment packages, both representative of actual clinical practice. To pretative of actual clinical practice. To preserve external validity, limits were set to serve external validity, limits were set to scientific rigour; there was no psychoscientific rigour; there was no psychotherapy plus placebo condition, nor an therapy plus placebo condition, nor an antidepressant plus sham psychotherapy antidepressant plus sham psychotherapy condition. The treating clinician emphacondition. The treating clinician emphasised to patients the importance of complisised to patients the importance of compliance, but there was no pill count nor ance, but there was no pill count nor plasma level confirmation. Our study did plasma level confirmation. Our study did not address questions about therapeutic not address questions about therapeutic factors. factors. The randomisation in our study appears The randomisation in our study appears successful. However, there is one statistisuccessful. However, there is one statistically significant difference between the cally significant difference between the treatment conditions, and it is one that treatment conditions, and it is one that possibly disadvantaged the psychotherapy possibly disadvantaged the psychotherapy arm: more patients in the psychotherapy arm: more patients in the psychotherapy condition (26%) than in the combined condition (26%) than in the combined therapy condition (14%) had undergone a therapy condition (14%) had undergone a psychiatric treatment during the present psychiatric treatment during the present episode, apparently to no avail, before episode, apparently to no avail, before entering the trial. entering the trial.
Acceptability Acceptability
More patients (99%) agreed to receive More patients (99%) agreed to receive psychotherapy than agreed to combined psychotherapy than agreed to combined therapy (84%). The fact that many therapy (84%). The fact that many depressed patients refused pharmacodepressed patients refused pharmacotherapy comes as no surprise; it is a daily therapy comes as no surprise; it is a daily problem in clinical practice. problem in clinical practice.
Feasibility Feasibility
The feasibility of a 6-month course of psyThe feasibility of a 6-month course of psychotherapy is fair. That the mean number chotherapy is fair. That the mean number of actual sessions was less than 16 was foreof actual sessions was less than 16 was foreseen, and is explicable; patients and theraseen, and is explicable; patients and therapists go on holiday, and sometimes they pists go on holiday, and sometimes they get influenza. More importantly, it is not get influenza. More importantly, it is not unusual for patient and therapist to agree unusual for patient and therapist to agree that a course of fewer than 16 sessions is that a course of fewer than 16 sessions is enough. To nobody's surprise, 25% of the enough. To nobody's surprise, 25% of the patients in the psychotherapy condition patients in the psychotherapy condition broke off their therapy. Interestingly, only broke off their therapy. Interestingly, only 16% did so in the combined therapy group. 16% did so in the combined therapy group. The difference is not statistically signifiThe difference is not statistically significant, but at least we can say that adding cant, but at least we can say that adding pharmacotherapy to psychotherapy is not pharmacotherapy to psychotherapy is not detrimental to the feasibility of the latter. detrimental to the feasibility of the latter.
The feasibility of 2 months of antiThe feasibility of 2 months of antidepressant therapy, in our study combined depressant therapy, in our study combined with psychotherapy, is fair: after 8 weeks with psychotherapy, is fair: after 8 weeks less than 10% of the patients had abanless than 10% of the patients had abandoned treatment. Long-term feasibility is doned treatment. Long-term feasibility is poor; nevertheless, after 20 weeks less than poor; nevertheless, after 20 weeks less than 30% of patients had withdrawn from the 30% of patients had withdrawn from the study. This result is above expectation; in study. This result is above expectation; in antidepressant research a drop-out rate up antidepressant research a drop-out rate up to 30% after 4-6 weeks of treatment is to 30% after 4-6 weeks of treatment is generally considered acceptable. Adding generally considered acceptable. Adding psychotherapy to pharmacotherapy seems psychotherapy to pharmacotherapy seems to improve the feasibility of the latter treatto improve the feasibility of the latter treatment. On the other hand, after 24 weeks of ment. On the other hand, after 24 weeks of treatment only 65% of the patients were treatment only 65% of the patients were still taking antidepressants. Again, this still taking antidepressants. Again, this accords with general research findings: accords with general research findings: poor compliance is a major problem in poor compliance is a major problem in any long-term medical treatment. any long-term medical treatment.
Efficacy Efficacy
Statistically significant and clinically releStatistically significant and clinically relevant improvements between the baseline vant improvements between the baseline assessment and week 24 are shown on all assessment and week 24 are shown on all instrument ratings in both treatment instrument ratings in both treatment groups. The magnitude of the improvement groups. The magnitude of the improvement is illustrated by the one group (pre-post) is illustrated by the one group (pre-post) effect sizes (see Table 5 ). The effect sizes effect sizes (see Table 5 ). The effect sizes vary but they are all large (defined as 0.8 vary but they are all large (defined as 0.8 or more by Cohen, 1988) . In this context, or more by Cohen, 1988) . In this context, the results of Lipsey & Wilson (1993) are the results of Lipsey & Wilson (1993) are interesting: these authors reported that the interesting: these authors reported that the mean one-group (pre-post) effect size of mean one-group (pre-post) effect size of psychological interventions is 0.76 (45 psychological interventions is 0.76 (45 meta-analyses). Another indicator of intrameta-analyses). Another indicator of intragroup improvement is the success rates at group improvement is the success rates at week 24 (see Table 6 ). In both conditions week 24 (see Table 6 ). In both conditions they vary from moderate to large. These they vary from moderate to large. These results corroborate the widely held view results corroborate the widely held view that combined therapy is an efficacious that combined therapy is an efficacious treatment of depression, and support the treatment of depression, and support the more controversial view that psychomore controversial view that psychotherapy too (in this case SPSP) is an therapy too (in this case SPSP) is an effective treatment of depression. effective treatment of depression.
Statistically significant inter-group difStatistically significant inter-group differences appear as early as week 4. Howferences appear as early as week 4. However, the relevance of these data is limited. ever, the relevance of these data is limited. In 4 weeks SPSP has not yet had a fair In 4 weeks SPSP has not yet had a fair chance to show its efficacy. Nobody exchance to show its efficacy. Nobody expects psychotherapy to provide rapid repects psychotherapy to provide rapid results. The main results (HRSD scores at sults. The main results (HRSD scores at week 24 in the per protocol sample) do week 24 in the per protocol sample) do not demonstrate statistically significant not demonstrate statistically significant differences between the treatment groups differences between the treatment groups (Table 7) . This result is corroborated by (Table 7) . This result is corroborated by the facts that the comparative HRSD effect the facts that the comparative HRSD effect size is small and that the survival analysis size is small and that the survival analysis does not indicate any superiority of comdoes not indicate any superiority of combined therapy over pharmacotherapy. In bined therapy over pharmacotherapy. In contradistinction to this, the SCL-D scores contradistinction to this, the SCL-D scores do show, in both the per protocol sample do show, in both the per protocol sample and the completers sample, statistically and the completers sample, statistically significant and clinically relevant intersignificant and clinically relevant intergroup differences, all of which favour group differences, all of which favour combined therapy over psychotherapy. combined therapy over psychotherapy. 
D E D E JON GHE E T A L J ON GHE E T A L
The comparative SCL-D effect size is 0.49, The comparative SCL-D effect size is 0.49, a value considered medium by Cohen a value considered medium by Cohen (1988) , and the survival analysis confirms (1988) , and the survival analysis confirms the superiority of combined therapy. Thus, the superiority of combined therapy. Thus, only the SCL-D consistently provides evionly the SCL-D consistently provides evidence supporting the view that combined dence supporting the view that combined therapy is more efficacious than psychotherapy is more efficacious than psychotherapy alone. In a previous study (de therapy alone. In a previous study (de Jonghe Jonghe et al et al, 2001) , in which we investi-, 2001), in which we investigated the advantages of combined therapy gated the advantages of combined therapy over over pharmacotherapy alone, we similarly pharmacotherapy alone, we similarly found that it was the SCL-D, rather found that it was the SCL-D, rather than the HRSD and the CGI, assessments than the HRSD and the CGI, assessments that consistently demonstrated significant that consistently demonstrated significant differences. differences.
Different instruments combined with Different instruments combined with different definitions of success unsurprisdifferent definitions of success unsurprisingly result in different success rates. In ingly result in different success rates. In addition, the emotional involvement of the addition, the emotional involvement of the observers differ: the HRSD scores deterobservers differ: the HRSD scores determined by therapy-independent, assumedly mined by therapy-independent, assumedly more neutral raters, the CGI scores by more neutral raters, the CGI scores by probably more optimistic clinicians who probably more optimistic clinicians who were evaluating the treatment they were evaluating the treatment they provided, and the SCL-D scores by patients provided, and the SCL-D scores by patients evaluating their own depression. The oneevaluating their own depression. The onegroup pre-post effect sizes computed at group pre-post effect sizes computed at week 24 in the total study group show week 24 in the total study group show that the clinician-CGI combination is that the clinician-CGI combination is considerably more optimistic than the considerably more optimistic than the patient-SCL-D or the observer-HRSD patient-SCL-D or the observer-HRSD combinations. The latter two seem to agree combinations. The latter two seem to agree quite well. The optimism of the clinicianquite well. The optimism of the clinician-CGI combination is also reflected in the CGI combination is also reflected in the fact that, if CGI success is defined as a score fact that, if CGI success is defined as a score of 1 or 2 on either the severity or the of 1 or 2 on either the severity or the 4 2 4 2 improvement scale, the success rates at improvement scale, the success rates at week 24 are 73% in the psychotherapy week 24 are 73% in the psychotherapy group and 81% in the combined therapy group and 81% in the combined therapy group. However, when it comes to possible group. However, when it comes to possible differences in efficacy between the differences in efficacy between the treatment conditions, the comparative treatment conditions, the comparative effect sizes at week 24 show that it is the effect sizes at week 24 show that it is the patients who detect a clinically meaningful patients who detect a clinically meaningful difference, not the clinicians or the independifference, not the clinicians or the independent raters. The last finding is the more dent raters. The last finding is the more noteworthy, considering that Hamilton noteworthy, considering that Hamilton (1967) intended the HRSD to be an instru-(1967) intended the HRSD to be an instrument suitable for the assessment of pharmament suitable for the assessment of pharmacotherapy, and hence deliberately selected cotherapy, and hence deliberately selected items he believed sensitive to antidepressant items he believed sensitive to antidepressant therapy. therapy.
Side-effects Side-effects
Combining antidepressant therapy with Combining antidepressant therapy with psychotherapy does not increase the psychotherapy does not increase the overall frequency of somatic complaints. overall frequency of somatic complaints. Unsurprisingly, dry mouth and excessive Unsurprisingly, dry mouth and excessive sweating were more frequent in the sweating were more frequent in the combined therapy group, but the more combined therapy group, but the more frequent occurrence of headache, nausea, frequent occurrence of headache, nausea, trembling or shaking and 'other comtrembling or shaking and 'other complaints' in the psychotherapy group seems plaints' in the psychotherapy group seems 4 3 4 3 
to be either a spurious or a mysterious to be either a spurious or a mysterious finding. finding.
Other relevant research Other relevant research
The paucity of studies investigating the The paucity of studies investigating the relative value of psychotherapy and comrelative value of psychotherapy and combined therapy in the treatment of depresbined therapy in the treatment of depression is striking. We found only seven sion is striking. We found only seven studies, five of which were published more studies, five of which were published more than 10 years ago, addressing this issue than 10 years ago, addressing this issue in ambulatory psychiatric patients with in ambulatory psychiatric patients with major depressive disorder and assessing major depressive disorder and assessing individual psychotherapy proper. Results individual psychotherapy proper. Results are not only scarce, they are also conflictare not only scarce, they are also conflicting. Three studies report the efficacy of ing. Three studies report the efficacy of combined therapy to be superior to that combined therapy to be superior to that of psychotherapy, whereas four do not find of psychotherapy, whereas four do not find a significant difference. In some respects a significant difference. In some respects our results seem to concur with those of our results seem to concur with those of Keller Keller et al et al (2000) , Blackburn (2000) , Blackburn et al et al (1981 Blackburn et al et al ( ) (1981 and Weissman and Weissman et al et al (1979) , who report a (1979), who report a superior efficacy of combined therapy over superior efficacy of combined therapy over psychotherapy. However, our main results psychotherapy. However, our main results seem to concur with those of Thase seem to concur with those of Thase et al et al (1997 ), Hollon (1997 , Hollon et al et al (1993 ), Beck (1993 , Beck et al et al (1985) and Murphy (1985) and Murphy et al et al (1981 Murphy et al et al ( ), who (1981 , who report an equal efficacy of both forms of report an equal efficacy of both forms of treatment. The main differences in design treatment. The main differences in design between the eight studies make comparibetween the eight studies make comparisons precarious. The patients in our study sons precarious. The patients in our study sample were certainly less severely sample were certainly less severely depressed than those studied by Keller depressed than those studied by Keller et et al al (2000) , all of whom had chronic depres- (2000), all of whom had chronic depression compared with 85% of our patients. sion compared with 85% of our patients. Depression in our sample was probably less Depression in our sample was probably less than in the 'more severe' subgroup and than in the 'more severe' subgroup and greater than in the 'less severe' subgroup greater than in the 'less severe' subgroup studied by Thase studied by Thase et al et al (1997) , who found (1997), who found a significant difference in efficacy in their a significant difference in efficacy in their former subgroup. Another consideration is former subgroup. Another consideration is that the length of our study (24 weeks) that the length of our study (24 weeks) was greater than that of the seven other was greater than that of the seven other studies. In addition, it may be mentioned studies. In addition, it may be mentioned that we studied both a per protocol and that we studied both a per protocol and an observed-cases sample, that in our study an observed-cases sample, that in our study the HRSD scores were assessed by an indethe HRSD scores were assessed by an independent observer, not by the treating pendent observer, not by the treating clinician, that we asked the opinion of clinician, that we asked the opinion of the patient, and that we worked with the patient, and that we worked with experienced psychotherapists or intensively experienced psychotherapists or intensively supervised residents. supervised residents.
Concluding remarks Concluding remarks
In summary, we investigated the possible In summary, we investigated the possible advantages of combining antidepressants advantages of combining antidepressants with psychotherapy in ambulatory patients with psychotherapy in ambulatory patients with mild to moderate major depressive with mild to moderate major depressive disorder. We found that psychotherapy is disorder. We found that psychotherapy is more acceptable than combined therapy. more acceptable than combined therapy. The 6-month feasibility of psychotherapy The 6-month feasibility of psychotherapy was fair, that of combined therapy was was fair, that of combined therapy was poor. None the less, both therapies were poor. None the less, both therapies were efficacious in reducing the symptoms of efficacious in reducing the symptoms of depression. The advantages of combining depression. The advantages of combining antidepressants with SPSP appeared equiantidepressants with SPSP appeared equivocal. Neither the treating clinicians nor vocal. Neither the treating clinicians nor the independent observers were able to the independent observers were able to ascertain them, but the patients experienced ascertain them, but the patients experienced them clearly. them clearly. 
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Protocol for pharmacotherapy Protocol for pharmacotherapy
Step 1 Step 1
All patients start with the serotonin^noradrenaline All patients start with the serotonin^noradrenaline reuptake inhibitor venlafaxine at a dosage of 75 mg reuptake inhibitor venlafaxine at a dosage of 75 mg per day. What happens afterwards depends on the per day. What happens afterwards depends on the duration of the treatment and the reaction of the duration of the treatment and the reaction of the patient (Table A1) . patient (Table A1) .
Step 2 Step 2
In case of venlafaxine intolerance or inefficacy, In case of venlafaxine intolerance or inefficacy, change the medication to a selective serotonin reupchange the medication to a selective serotonin reuptake inhibitor (SSRI). Preference is given to fluoxetine take inhibitor (SSRI). Preference is given to fluoxetine or, as a second option, fluvoxamine. However, the or, as a second option, fluvoxamine. However, the choice can be influenced by the patient's preference choice can be influenced by the patient's preference or treatment history. The chosen SSRI is prescribed or treatment history. The chosen SSRI is prescribed according to a specific guideline, different but comaccording to a specific guideline, different but comparable with that described in step 1 (further details parable with that described in step 1 (further details available from the authors upon request). available from the authors upon request).
Step 3 Step 3 In case of SSRI intolerance or inefficacy, the In case of SSRI intolerance or inefficacy, the medication is switched to nortriptyline, a trimedication is switched to nortriptyline, a tricyclic antidepressant, at a dosage of 50 mg per cyclic antidepressant, at a dosage of 50 mg per day. What happens afterwards depends on the day. What happens afterwards depends on the duration of the treatment and the reaction of the duration of the treatment and the reaction of the patient (Table A2) . patient (Table A2) .
Step 4 Step 4
In case of nortriptyline inefficacy, lithium is added. In case of nortriptyline inefficacy, lithium is added. The preference of the patient may determine the choice between psychotherapy and combined therapy. and combined therapy.
LIMITATIONS LIMITATIONS
& & The study population was restricted to ambulatory patients presenting with a
The study population was restricted to ambulatory patients presenting with a major depressive disorder of mild or moderate severity. major depressive disorder of mild or moderate severity. 
